Moulis et al reported clinical findings associated with newly diagnosed immune thrombocytopenia (ITP) in adults. The authors are from multiple institutions in France.
Patient selection: adult with new onset of immune thrombocytopenia
Bleeding symptoms:
(1) cutaneous
(2) mucosa of head and neck (epistaxis, oral)
(3) gastrointestinal
(4) hematuria
(5) central nervous system
Key risk factors for the ITP:
(1) autoimmune disease
(2) infection within the 6 weeks prior to onset
Other factors:
(1) myelodysplasia
(2) malignancy
(3) targeted agent (adalimumab)
Predictors of chronic ITP:
(1) antinuclear antibody positive
Predictors of therapy with intravenous corticosteroids (methylprednisolone) and/or intravenous immunoglobulin (IVig):
(1) Khellaf bleeding score > 8 (range 0 to 35)
(2) platelet count <= 10,000 per µL
Criteria for recovery - all of the following:
(1) >= 2 platelet counts >= 150,000 per µL at least 7 days apart
(2) absence of bleeding
(3) absence of ITP treatment
